BTC Network — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$340,229	29
2020	Research	$152,685	37
2019	Research	$47,100	4

Breakdown

Who paid Research payments · program years 2019–2021

Pfizer Inc. $285,169 10 payments
BioCryst Pharmaceuticals, Inc. $125,438 36 payments
Octapharma USA, Inc. $42,073 5 payments
Supernus Pharmaceuticals, Inc. $36,545 2 payments
Biohaven Pharmaceuticals, Inc. $35,560 13 payments
VYNE Pharmaceuticals Inc. $15,228 4 payments

Studies the money was for Research payments · program years 2019–2021

A Phase 3 Randomized Doubleblind Placebocontrolled Study to Evaluate the Safety Tolerability and Immunogenicity of 3 Lots of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Healthy Adults $285,169 10 payments
An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema $125,438 36 payments
Scgam-06 $42,073 5 payments
Evaluation of Spn-812 Er 400 and 600 MG Efficacy and Safety in Adolescents With Adhd - A Double-Blind, Placebo- Controlled, Pivotal Trial $36,545 2 payments
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $21,250 9 payments
Mti-117 $15,228 4 payments
BHV3500-301: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $8,550 1 payment
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $4,513 2 payments
A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $1,247 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.